Dyne Therapeutics (DYN) Gains from Investment Securities (2019 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Gains from Investment Securities of $149713.0 in Q1 2026, down 93.49% quarter-over-quarter from $2.3 million in Q4 2025, and down 98.3% on a YoY basis from $8.8 million in Q1 2025.
Dyne Therapeutics (DYN) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Dyne Therapeutics' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at $149713.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 98.3% year-over-year to $149713.0; the TTM figure through Mar 2026 stood at $149713.0 (down 98.3% YoY), while the FY2025 annual figure was $9.9 million, up 14.16% from the prior year.
- Gains from Investment Securities was $149713.0 for Q1 2026 at Dyne Therapeutics, down from $2.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $9.2 million in Q2 2023 to a low of -$8.0 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged $1.2 million across 5 years, with a median of $297924.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities plunged 2085.79% in 2023, then jumped 25655.56% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$366000.0 in 2022, then slumped by 2085.79% to -$8.0 million in 2023, then jumped by 99.89% to -$9000.0 in 2024, then surged by 25655.56% to $2.3 million in 2025, then sank by 93.49% to $149713.0 in 2026.
- The last three Gains from Investment Securities figures came in at $149713.0 (Q1 2026), $2.3 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149,713.00 |
| Mar 31, 2026 | 149,713.00 |
| Dec 31, 2025 | 2.30 Mn |
| Dec 31, 2025 | 2.30 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Dec 31, 2024 | -9,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Sep 30, 2024 | 487,872.00 |
| Sep 30, 2024 | 487,872.00 |
| Jun 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 297,924.00 |
| Mar 31, 2024 | 297,924.00 |
| Dec 31, 2023 | -8.00 Mn |
| Dec 31, 2023 | -8.00 Mn |